Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is September 5, 2025, covering a share repurchase executed on September 4, 2025. The transaction was conducted through Merrill Lynch International as part of an existing non-discretionary buyback agreement initiated on June 4, 2025.
Key Financial Metrics
- Shares Purchased (Current Transaction): 284,800 ordinary shares.
- Price Range (Current Transaction): Lowest 1,451.00 GBp; Highest 1,472.50 GBp.
- Volume-Weighted Average Price (Current Transaction): 1,464.66 GBp.
- Cumulative Shares Purchased (Since June 4, 2025): 27,315,467 ordinary shares.
- Total Treasury Shares Held: 245,449,850 ordinary shares.
- Ordinary Shares in Issue (Excluding Treasury): 4,069,946,246.
- Total Voting Rights: 4,069,946,246.
- Treasury Share Voting Percentage: 6.03%.
Material Changes
The filing details a reduction in the number of shares outstanding through the acquisition of treasury stock. Since the commencement of the current buyback program on June 4, 2025, the company has reduced its share count by over 27 million shares. The specific transaction on September 4, 2025, added approximately 285,000 shares to the treasury holding. No other material changes to revenue, profit, or debt are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and the Q2 Results for 2025. The filing confirms the purchase was effected pursuant to a non-discretionary agreement, indicating a structured approach to capital return.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback program announced on June 4, 2025.
- Confirm the impact of the 6.03% treasury share holding on earnings per share (EPS) calculations.
- Review the "Risk Factors" in the 2024 Form 20-F and Q2 2025 results for context on the company's broader financial health.
- Check subsequent filings for updates on the buyback program's completion status or extension.